ClinicalTrials.gg

Program

acalabrutinib

Also written as “Acalabrutinib”, “ACP-196” and “Acalabrutinib (ACP-196)”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Mantle-Cell · Lymphoma, Large B-Cell, Diffuse · COVID-19 · Hepatic Insufficiency, led by 4 companies.

Furthest: phase 4, since Jun 11, 202155 company-led studies, 22 open or runningNext primary completion: Feb 15, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca5220 open or runningphase 4since Jun 11, 2021Jan 6, 2014Feb 15, 2027phase 3 · NCT02972840
AbbVie11 open or runningphase 3since May 20, 2024May 20, 2024Mar 2028phase 3 · NCT06428019
Ascentage Pharma Group International11 open or runningphase 3since Mar 13, 2024Mar 13, 2024Aug 2027phase 3 · NCT06319456
Ipsen10 open or runningphase 2since Dec 29, 2021Dec 29, 2021none ahead

Also a collaborator on its studies: Apices Soluciones S.L., Hoffmann-La Roche, Fortrea, eResearch Technology, CISCRP, Parexel, Merck and Eli Lilly.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 37 studies since Jan 6, 2014.

  1. Apr 28, 20212 phase 1 studiesAstraZeneca · NCT04867980, NCT04867941
  2. May 5, 20215 phase 1 studiesAstraZeneca · NCT04876807, NCT04901923, NCT04914936 and 2 more
  3. Jun 11, 2021Phase 4 study in Leukemia, Lymphocytic, Chronic, B-CellAstraZeneca · NCT04930536 · 103 enrolled · India
  4. Sep 16, 2021Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellAstraZeneca · NCT05057494 · 607 enrolled · United States, Australia, Czechia and more
  5. Dec 29, 2021Ipsen’s first study: phase 2 study in Hematologic NeoplasmsNew to IpsenIpsen · NCT05205252 · United States
  6. Jun 5, 2023Phase 2 study in Lymphoma, Mantle-CellAstraZeneca · NCT05951959 · 108 enrolled · United States, Australia, Brazil and more
  7. Jul 11, 2023Phase 2 study in Lymphoma, Large B-Cell, DiffuseAstraZeneca · NCT05952024 · 80 planned · United States, Brazil, Puerto Rico and more
  8. Mar 13, 2024Ascentage Pharma Group International’s first study: phase 3 study in CLL/SLLNew to Ascentage Pharma Group InternationalAscentage Pharma Group International · NCT06319456 · 344 planned · China
  9. May 20, 2024AbbVie’s first study: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNew to AbbVieAbbVie · NCT06428019 · 170 planned · United States, Australia, France and more
  10. Aug 20, 2024Phase 4 study in Leukemia, B-CellAstraZeneca · NCT06651970 · 60 planned · United States, Czechia, Italy and more
  11. Jan 21, 2025Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellAstraZeneca · NCT06839872
  12. May 26, 2025Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellAstraZeneca · NCT07024706 · 80 planned · United States, Austria, Brazil and more
  13. Jun 12, 2025Phase 2 study in Lymphoma, Mantle-CellAstraZeneca · NCT07029737 · 55 planned · Spain
  14. Oct 5, 2026Primary completion moved from 2027-01-31 to 2027-04-30Date moved laterphase 3 · +3 months · NCT03836261

Ahead

  1. Feb 15, 2027Primary completion: phase 3 study in Lymphoma, Mantle-CellAstraZeneca · NCT02972840
  2. Feb 22, 2027Primary completion: phase 3 study in Lymphoma, Large B-Cell, DiffuseAstraZeneca · NCT04529772
  3. Apr 30, 2027Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellAstraZeneca · NCT03836261
  4. Jul 15, 2027Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellAstraZeneca · NCT05057494

TargetBeta

BTK →read by rule
“An orally available inhibitor of Bruton's tyrosine kinase (BTK) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor; Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313
birelentinibruleDizal Pharmaceuticalsphase 312

Studies

All 55 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07029737Lymphoma, Mantle-Cell · Spain2RecruitingAstraZenecaDec 31, 202755
NCT07024706Leukemia, Lymphocytic, Chronic, B-Cell · United States, Austria, Brazil and more2RecruitingAstraZenecaMay 1, 202980
NCT06839872Leukemia, Lymphocytic, Chronic, B-Cell2WithdrawnAstraZenecaJul 28, 20280
NCT06651970Leukemia, B-Cell · United States, Czechia, Italy and more4RecruitingAstraZenecaSep 30, 203260
NCT06428019Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more3RecruitingAbbVieMar 2028170
NCT06319456CLL/SLL · China3RecruitingAscentage Pharma Group InternationalAug 2027344
NCT05952024Lymphoma, Large B-Cell, Diffuse · United States, Brazil, Puerto Rico and more2RecruitingAstraZenecaApr 22, 202980
NCT05951959Lymphoma, Mantle-Cell · United States, Australia, Brazil and more2Active, not recruitingAstraZenecaOct 31, 2028108
NCT05205252Hematologic Neoplasms · United States2WithdrawnIpsenJul 5, 20230
NCT05057494Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Czechia and more3Active, not recruitingAstraZenecaJul 15, 2027607
NCT04930536Leukemia, Lymphocytic, Chronic, B-Cell · India4CompletedAstraZenecaMay 2, 2023103
NCT04905043Healthy Volunteers · United States1CompletedAstraZenecaJul 11, 201612
NCT04914936Healthy Participants · United States1CompletedAstraZenecaOct 16, 201472
NCT04898101Healthy Volunteers · United States1CompletedAstraZenecaApr 13, 201614
NCT04901923Healthy Participants · United States1CompletedAstraZenecaMay 22, 201459
NCT04876807Healthy Volunteers · United States1CompletedAstraZenecaMar 15, 201636
NCT04867980Healthy Volunteers · United States1CompletedAstraZenecaMay 9, 201648
NCT04867941Hepatic Insufficiency · United States1CompletedAstraZenecaFeb 2, 201518
NCT04768985Bioequivalence · United States1CompletedAstraZenecaMay 10, 202166
NCT04564040Lymphoma, Mantle-Cell · Germany1CompletedAstraZenecaDec 11, 202020
NCT04529772Lymphoma, Large B-Cell, Diffuse · United States, Australia, Austria and more3Active, not recruitingAstraZenecaFeb 22, 2027611
NCT04489797Communicable Diseases · United States1CompletedAstraZenecaAug 28, 202035
NCT04497948COVID-19 · Brazil1TerminatedAstraZenecaNov 18, 20209
NCT04435483Pharmacokinetics · United States1CompletedAstraZenecaJun 26, 202039
NCT04380688COVID-19 · United States2CompletedAstraZenecaNov 16, 202062
NCT04346199COVID-19 · Argentina, Brazil, Chile and more2CompletedAstraZenecaNov 17, 2020177
NCT04075292Leukemia, Lymphocytic, Chronic, B-Cell · China, Philippines, Taiwan and more3Active, not recruitingAstraZenecaJan 3, 2024155
NCT04008706Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Brazil and more3CompletedAstraZenecaNov 4, 2025552
NCT03968848Hepatic Insufficiency · United States1CompletedAstraZenecaMar 13, 201916
NCT03932331Lymphoma, Mantle-Cell · China2Active, not recruitingAstraZenecaDec 22, 2022105
NCT03836261Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more3Active, not recruitingAstraZenecaApr 30, 2027984
NCT03205046DLBCL · United States, United Kingdom2TerminatedAstraZenecaNov 20, 201925
NCT03198650Part1: Advanced B-cell Malignancies · Japan1CompletedAstraZenecaOct 27, 202235
NCT02972840Lymphoma, Mantle-Cell · United States, Argentina, Australia and more3Active, not recruitingAstraZenecaFeb 15, 2027635
NCT02970318Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more3Active, not recruitingAstraZenecaSep 3, 2021310
NCT02735876Lymphoma, Mantle-Cell3WithdrawnAstraZenecaJun 20200
NCT02717611Leukemia, Lymphocytic, Chronic, B-Cell · United States, Belgium, France and more2Active, not recruitingAstraZenecaOct 16, 202060
NCT02717624Lymphoma, Mantle-Cell · United States, Italy, Poland1Active, not recruitingAstraZenecaJun 15, 202272
NCT02586857Glioblastoma · United States2Active, not recruitingAstraZenecaJun 26, 202024
NCT02537444Ovarian Neoplasms · United States2CompletedAstraZenecaJul 201878
NCT02477696Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more3Active, not recruitingAstraZenecaSep 15, 2020533
NCT02475681Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more3CompletedAstraZenecaFeb 8, 2019535
NCT02454179Squamous Cell Carcinoma of Head and Neck · United States2CompletedAstraZenecaMay 201878
NCT02448303Carcinoma, Non-Small-Cell Lung · United States2CompletedAstraZenecaMar 201874
NCT02387762Arthritis, Rheumatoid · United States2CompletedAstraZenecaMay 201631
NCT02362035Lymphoma, Follicular · United States2CompletedAstraZenecaJul 14, 2020161
NCT02362048Pancreatic Neoplasms · United States2CompletedAstraZenecaMar 201777
NCT02351739Carcinoma, Transitional Cell · United States2CompletedAstraZenecaFeb 201878
NCT02337829Leukemia, Lymphocytic, Chronic, B-Cell · United States2CompletedAstraZenecaJun 26, 202048
NCT02213926Lymphoma, Mantle-Cell · United States, Australia, Belgium and more2Active, not recruitingAstraZenecaDec 4, 2020124
NCT02211014Multiple Myeloma · United States, United Kingdom1CompletedAstraZenecaApr 26, 201927
NCT02180724Waldenstrom Macroglobulinemia · United States, France, Greece and more2Active, not recruitingAstraZenecaOct 1, 2019107
NCT02180711Lymphoma, Non-Hodgkin · United States, Canada, Italy2Active, not recruitingAstraZenecaAug 25, 2023113
NCT02112526Lymphoma, Large B-Cell, Diffuse · United States, United Kingdom1CompletedAstraZenecaJun 30, 202021
NCT02029443Leukemia, Lymphocytic, Chronic, B-Cell · United States, Italy, United Kingdom2Active, not recruitingAstraZenecaJul 15, 2021306

How it is read

Names in the registry

  • “Acalabrutinib”, 28 entries
  • “acalabrutinib”, 7 entries
  • “ACP-196”, 7 entries
  • “Acalabrutinib (ACP-196)”, 3 entries
  • “ACP-196 (acalabrutinib)”, 2 entries

Codes read as this program: ACP196.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.